LBA16 - Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study
| Autor: | Zhu, A.X., Ryoo, B.Y., Yen, C.J., Kudo, M., Poon, R., Pastorelli, D., Blanc, J-F., Chung, H.C., Baron, A.D., Pfiffer, T.E.F., Okusaka, T., Kubackova, K., Trojan, J., Sastre, J., Chau, I., Chang, S-C., Abada, P.B., Yang, L., Schwartz, J.D., Park, J.O. |
|---|---|
| Zdroj: | In Annals of Oncology September 2014 25 Supplement 4:v1-v1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|